You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
The test, which is in development using perspiration as a sample, has shown promising performance in a preliminary study.
The Finnish company also announced that it has received CE-IVD marking for its Aiforia Clinical pathology image analysis platform.
The German molecular diagnostics firm is preparing for its merger with US-based OpGen, which is slated to close in the first quarter of next year.
Northern California healthcare system NorthBay Healthcare will evaluate the platform's ability to improve the routine use of genetic testing.
The firms are collaborating to provide reference architectures for whole-slide image viewing and managing to healthcare and life sciences organizations.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
The company's software-related revenues grew year over year, but its sequencing and molecular analysis revenues declined.
The digital pathology company, which pulled in $60 million earlier this year, said it has raised over $90 million since it was founded in 2016.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The Eudamed database is an integral part of the new Medical Device and IVD Regulations that go into effect in 2020 and 2022.
The educational grant will support UpToDate's development of technology to help medical professionals advise their patients on health implications of genetic tests.
The company offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
While some large health systems have developed internal tools for lab test utilization, a number of outside vendors are rolling out solutions of their own.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
The funding is being provided by the Flemish government's Agency for Innovation and Entrepreneurship to support the three-year development project.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.